Roivant Sciences (NASDAQ:ROIV) Given New $33.00 Price Target at The Goldman Sachs Group

Roivant Sciences (NASDAQ:ROIV) had its price target hoisted by stock analysts at The Goldman Sachs Group from $24.00 to $33.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s price target suggests a potential upside of 50.10% from the company’s previous close.

A number of other equities research analysts also recently weighed in on ROIV. JPMorgan Chase & Co. lifted their target price on Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Thursday, September 18th. Wall Street Zen upgraded shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. Guggenheim reiterated a “buy” rating and set a $25.00 target price on shares of Roivant Sciences in a research report on Friday, November 14th. Citigroup raised their price target on shares of Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Finally, HC Wainwright lifted their price target on shares of Roivant Sciences from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $24.81.

Roivant Sciences Stock Down 0.5%

Roivant Sciences stock traded down $0.12 during trading hours on Monday, reaching $21.99. 3,348,188 shares of the company’s stock were exchanged, compared to its average volume of 6,537,190. The firm’s 50 day simple moving average is $19.38 and its 200 day simple moving average is $14.73. Roivant Sciences has a twelve month low of $8.73 and a twelve month high of $22.56. The firm has a market capitalization of $15.29 billion, a PE ratio of -39.19 and a beta of 1.22.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 539,650 shares of Roivant Sciences stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $20.51, for a total transaction of $11,068,221.50. Following the completion of the transaction, the insider owned 33,653,756 shares in the company, valued at approximately $690,238,535.56. The trade was a 1.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Allen Gold sold 1,300,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $20.23, for a total value of $26,299,000.00. Following the sale, the director directly owned 18,047,727 shares of the company’s stock, valued at $365,105,517.21. This represents a 6.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,907,812 shares of company stock valued at $125,271,540 over the last three months. Corporate insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Allworth Financial LP lifted its position in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares in the last quarter. Swiss Life Asset Management Ltd purchased a new stake in shares of Roivant Sciences during the third quarter valued at approximately $217,000. Danske Bank A S bought a new stake in Roivant Sciences during the third quarter worth $138,000. XTX Topco Ltd purchased a new position in Roivant Sciences in the third quarter worth $1,067,000. Finally, Alyeska Investment Group L.P. grew its stake in Roivant Sciences by 326.7% in the 3rd quarter. Alyeska Investment Group L.P. now owns 494,455 shares of the company’s stock valued at $7,481,000 after purchasing an additional 378,589 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.